Skip to main content Back to Top
Advertisement

7/18/2022

Diazepam Injection

Products Affected - Description

    • Diazepam injection, DASH Pharmaceuticals, LLC, 5 mg/mL, 2 mL Luer Lock syringe, 10 count, NDC 69339-0136-34
    • Diazepam injection, Hikma, 5 mg/mL, 2 mL vial, 10 count, NDC 00641-6244-10
    • Diazepam injection, Pfizer, 5 mg/mL, 10 mL vial, 10 count, NDC 00409-3213-12
    • Diazepam injection, Pfizer, 5 mg/mL, 2 mL Carpuject syringe, 10 count, NDC 00409-1273-32

Reason for the Shortage

    • DASH has diazepam injection on shortage due to increased demand.
    • Hikma did not provide a reason for the shortage.
    • Pfizer has diazepam injection on shortage due to increased demand.

Available Products

    • Diazepam injection, DASH Pharmaceuticals, LLC, 5 mg/mL, 10 mL vial, 5 count, NDC 69339-0137-05

Estimated Resupply Dates

    • DASH has diazepam 5 mg/mL 2 mL Luer Lock syringes on allocation.
    • Hikma has diazepam 5 mg/mL 2 mL vials on back order and the company estimates a release date of late-August to early-September 2022.
    • Pfizer has diazepam 5 mg/mL 2 mL Carpuject syringes on back order and the company estimates a release date of July 2022. The 10 mL vials are available in limited supply.

Updated

Created July 18, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.